Refractory VT/VF, Prospective Evaluation to Differentiate Lidocaine Efficacy from Nifekalant
Not Applicable
- Conditions
- Ventricular tachycardia, Ventricular fibrillation
- Registration Number
- JPRN-UMIN000001781
- Lead Sponsor
- Japan Medical Promotion Agency
- Brief Summary
After treatment of nifekalant, 23 of 27 patients showed termination of VF/VT, as compared with 15 of 28 patients treated with lidocaine (P=0.03) with/without additional shock.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 55
Inclusion Criteria
Not provided
Exclusion Criteria
Drug-induced long QT syndrome Congenital long QT syndrome
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Termination of VT/VF with/without shock
- Secondary Outcome Measures
Name Time Method Return of spontaneous circulation, One-month survival, Discharge alive from the hospital, Adverse events: asystole,pulseless electrical activity, Torsades de pointes, QT prolongation(>0.55)